Immune Implications of Cholesterol-Containing Lipid Nanoparticles
Open Access
- 10 October 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (42) , 28480-28501
Abstract
The majority of clinically approved nanoparticle-mediated therapeutics are lipid nanoparticles (LNPs), and most of these LNPs are liposomes containing cholesterol. LNP formulations significantly alter the drug pharmacokinetics (PK) due to the propensity of nanoparticles for uptake by macrophages. In addition to readily engulfing LNPs, the high expression of cholesterol hydroxylases and reactive oxygen species (ROS) in macrophages suggests that they will readily produce oxysterols from LNP-associated cholesterol. Oxysterols are a heterogeneous group of cholesterol oxidation products that have potent immune modulatory effects. Oxysterols are implicated in the pathogenesis of atherosclerosis and certain malignancies; they have also been found in commercial liposome preparations. Yet, the in vivo metabolic fate of LNP-associated cholesterol remains unclear. We review herein the mechanisms of cellular uptake, trafficking, metabolism, and immune modulation of endogenous nanometer-sized cholesterol particles (i.e., lipoproteins) that are also relevant for cholesterol-containing nanoparticles. We believe that it would be imperative to better understand the in vivo metabolic fate of LNP-associated cholesterol and the immune implications for LNP-therapeutics. We highlight critical knowledge gaps that we believe need to be addressed in order to develop safer and more efficacious lipid nanoparticle delivery systems.Keywords
Funding Information
- National Institutes of Health (CA282339)
This publication has 251 references indexed in Scilit:
- From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain BarrierAdvanced Therapeutics, 2020
- Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunityMolecular Oncology, 2020
- Oxysterol mixture and, in particular, 27‐hydroxycholesterol drive M2 polarization of human macrophagesBioFactors, 2015
- Cholesterol Efflux and Reverse Cholesterol Transport2014
- Death‐signaling pathways in human myeloid cells by oxLDL and its cytotoxic components 7β‐hydroxycholesterol and cholesterol‐5β,6β‐epoxideJournal of Biochemical and Molecular Toxicology, 2007
- Multiplexed flow cytometric analyses of pro‐ and anti‐inflammatory cytokines in the culture media of oxysterol‐treated human monocytic cells and in the sera of atherosclerotic patientsCytometry Part A, 2006
- Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDLJournal of Molecular Medicine, 2006
- Activation of caspase-3-dependent and -independent pathways during 7-ketocholesterol- and 7β-hydroxycholesterol-induced cell death: A morphological and biochemical studyJournal of Biochemical and Molecular Toxicology, 2005
- Evidence that macrophages transfer arachidonic acid and cholesterol to tissues in vivoCell Biochemistry and Function, 2003
- Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia2000